The recent recognition of the eosinophiliamyalgia syndrome (EMS) associated with the ingestion of L-tryptophan prompted an analysis of the peripheral blood eosinophil phenotypes and of the serum eosinophil hematopoietins in this disorder. Five patients with an illness characterized by the abrupt onset of aching skeletal muscles, edema, thickening and induration of the skin, and marked blood eosinophilia associated with L-tryptophan ingestion provided eosinophils, serum, or both, for evaluation. Gradient sedimentation density analysis of the peripheral blood eosinophils from four of these patients revealed that 43 + 13% (mean ± SEM) of the cells had converted to the abnormal (hypodense) sedimenting phenotype. When normodense eosinophils from the reference donors were cultured for 3 days in medium supplemented with increasing concentrations of serum from the patients with EMS, their viability increased in a dose-dependent manner to 45%, which was significantly augmented over the effect of normal serum. This eosinophil viability-sustaining activity was inhibited by 76 ± 7% (mean ± SEM; n = 3) by the addition of anti-interleukin 5 (IL-5) but not by neutralizing antibodies monospecific for either granulocyte/macrophage colonystimulating factor (GM-CSF) or IL-3. IL-5, an eosinophilopoietic factor, converts normodense peripheral blood eosinophils in vitro to a hypodense sedimenting form with extended viability and augmented biologic responses to activating stimuli. Thus, the presence of IL-5 in the sera of patients with EMS may contribute to the development and maintenance of the eosinophilia and may regulate the conversion of the peripheral blood eosinophils to the hypodense phenotype with augmented pathobiologic potential.
inhibited by 76 ± 7% (mean ± SEM; n = 3) by the addition of anti-interleukin 5 (IL-5) but not by neutralizing antibodies monospecific for either granulocyte/macrophage colonystimulating factor (GM-CSF) or IL-3. IL-5, an eosinophilopoietic factor, converts normodense peripheral blood eosinophils in vitro to a hypodense sedimenting form with extended viability and augmented biologic responses to activating stimuli. Thus, the presence of IL-5 in the sera of patients with EMS may contribute to the development and maintenance of the eosinophilia and may regulate the conversion of the peripheral blood eosinophils to the hypodense phenotype with augmented pathobiologic potential.
The eosinophilia-myalgia syndrome (EMS), associated with the ingestion of L-tryptophan, is characterized by peripheral blood eosinophilia, myalgia, thickened and indurated skin, and peripheral edema (1) (2) (3) (4) (5) (6) (7) . The histologic changes include edema, cellular infiltration, and fibrosis of the dermis, fascia, and muscle. The perivascular infiltration by lymphocytes, plasma cells, and eosinophils is accompanied by the deposition of eosinophil granule proteins (6) . Despite the prominence of the peripheral blood eosinophilia in EMS, the phenotype of the eosinophils and the putative cytokine(s) responsible for the development of the eosinophilia have not been determined.
Eosinophils isolated from the peripheral blood of patients with the idiopathic hypereosinophilic syndrome (IHES), asthma, and helminthic infections have a lower mean gradient sedimentation density (hypodense) than that of eosinophils purified from healthy individuals (normodense) (8) (9) (10) (11) (12) . In comparison with normodense eosinophils, hypodense eosinophils generate increased amounts of leukotriene C4 (LTC4) in response to stimulation with calcium ionophore A23187 and have an augmented capacity to mediate antibodydependent cytotoxicity (10, 11) . Normodense eosinophils cultured in vitro with picomolar concentrations of granulocyte/macrophage colony-stimulating factor (GM-CSF), interleukin 3 (IL-3), or interleukin 5 (IL-5) maintain their viability for at least 14 days and are converted to a hypodense phenotype that is primed for enhanced calcium ionophoreinitiated LTC4 generation and antibody-mediated cytotoxicity (13) (14) (15) . The presence of IL-5 in the serum of patients with IHES suggests that this hematopoietin plays a regulatory role when some of the peripheral blood eosinophils express the hypodense phenotype with augmented viability and function (16) . We studied the eosinophil phenotypes and associated cytokine activities in the blood of patients with EMS.
MATERIALS AND METHODS
Patients. Five Caucasian females with a mean ± SEM age of 55 ± 7 years who ingested L-tryptophan for a mean ± SEM period of 19 ± 7 months in usual doses ranging from 500 to 2000 mg/day (mean ± SEM, 1280 ± 252) were identified with peripheral blood eosinophilia, a clinical course consistent with the recently described EMS, and a history of L-tryptophan ingestion (Table 1) . Their charts were reviewed retrospectively, and the patients were followed as clinically indicated. All patients were examined by at least one of the authors (R.J.A.).
Myalgia, which was usually abrupt in onset and severe, caused subjective weakness. Arthralgia, without joint warmth or swelling, occurred in the shoulders, wrists, knees, and ankles. Paresthesias involved the forearms and legs in two patients, and the hands and feet in one. Pruritus was generalized. Other concomitant symptoms or signs among the individual patients included alopecia, dry cough, fatigue, lightheadedness, morning stiffness, low grade fever, discomfort at a site of prior incision and radiation therapy, shortness of breath, dry mouth, dysphagia, and an influenza-like prodrome.
On physical examination, skin thickening and induration involved the calves and the medial aspect of the upper inner arms. The chest, abdomen, and thighs were also involved in two patients, and the hands in only one. When present, macular erythema overlay the regions of skin thickening. Shoulder and/or hip range of motion was mildly limited in all patients except one.
All patients had peripheral blood eosinophilia ( 
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The statistical significance for the difference in the vial of eosinophils cultured with serum from individual pati with EMS and with serum from individual reference do was determined by the two-tailed Student t test.
RESULTS
Sedimentation Gradient Profile of Eosinophils. Eosinol isolated from the reference donors were predominantly modense; only 9 ± 4% were hypodense (mean + SEM; 7) (Fig. 1A) . The normodense eosinophil gradient fract from the reference donors contained 82 ± 15% eosinor and 18 ± 12% neutrophils. Of the eosinophils isolated f patients 1-4 with EMS, 43 ± 13% (mean ± SEM; P < 0 were hypodense (Fig. 1B) ; these fractions contained 20 ± eosinophils, 55 ± 12% neutrophils, and 25 ± 15% monc clear cells. The normodense eosinophil gradient fracti from these same four patients with EMS contained 89 + eosinophils and 11 ± 5% neutrophils.
Viability-Sustaining Activity in Serum from Patients i EMS and Its Neutralization with Antibody. Freshly isolk normodense eosinophils from reference donors were tured in enriched medium supplemented with increaw concentrations of serum from patients with EMS or fi culcompared with a mean viability of45% when the medium was sing supplemented with the same dilution of serum from patients rom with EMS. Anti-IL-3 and anti-GM-CSF completely neutralized the viability-sustaining activity of 10 pM IL-3 and 10 pM GM-CSF at a dilution of '1:5000 and at a concentration of .5 ! g/ml, respectively. At a standard dilution of 1:250 for anti-IL-3 and at concentrations of 100 ,ug/ml for anti-GM-CSF and 20 ,ug/ml for anti-IL-5, no cross-neutralizing activity was noted, as defined by inhibition of the viabilitysustaining activity for eosinophils maintained with the appropriate cytokine. Anti-IL-5 neutralized the viabilitysustaining activity of 1 pM human IL-5 in a dose-dependent manner, and complete neutralization occurred at concentrations of .1.0 ,ug/ml. Bovine serum albumin-Sepharose at concentrations as great as 100 pug/ml had no effect. Preabsorption of 50% serum from patients 1, 2, and 5 with 20 ,ug of anti-IL-5 diminished mean eosinophil viability after 72 hr of culture from 51 + 4% to 18 + 4% (P < 0.05) (Fig. 3) , a net inhibition of 75%. Neither anti-GM-CSF nor anti-IL-3 reduced the viability of normodense eosinophils maintained for 72 hr in enriched medium supplemented with 50% serum from the patients with EMS. The viability of replicate normodense eosinophils maintained in enriched medium alone was 7 ± 1% (mean ± SEM; n = 3). DISCUSSION Five patients with an illness characterized by the abrupt onset of myalgia associated with edema, thickening and induration of the skin, and peripheral blood eosinophilia associated with the ingestion of L-tryptophan were considered to have the recently described EMS (1-7) . Macular erythema, when present in these patients, was superimposed on the thickening and induration of the affected skin. Paresthesias and hyperesthesia were common, but axonal neurMedical Sciences: Owen et al. --: --. -, , : , . , Ã. . . . . . . . . . . . . . . opathy with motor weakness was not seen. In addition to the marked eosinophilia, the patients exhibited depressed creatine phosphokinase activity as noted in earlier reports (4) but no concurrent elevation of serum aldolase activity. There appeared to be no internal organ involvement, with the possible exception of reversible heart failure in patient 1. On biopsy, the dermis, subcutaneous tissue, fascia, and even muscle showed infiltration with mononuclear cells and some eosinophils in varying proportions with mild to moderate fibrosis, and perineurial, endoneurial, endomysial, perimysial, and endovascular infiltrations.
The sedimentation density gradient profile of the peripheral blood eosinophils from the patients with EMS revealed a shift to the hypodense phenotype as compared with eosinophils from reference donors (Fig. 1) . The transition fraction of 21/22% was included in defining the hypodense population because the distribution profile was different for the two groups. Because this phenotypic change occurs to a greater degree in the peripheral blood eosinophils from patients with IHES (16) , or ex vivo in normodense eosinophils from normal donors exposed for 7 days to picomolar concentrations of GM-CSF, IL-3, or IL-5 (13) (14) (15) , the eosinophils in this fraction were not used previously by our group in defining hypodensity. The serum of patients with EMS elicited a significant dose-dependent increase in the ex vivo viability of eosinophils of normal donors as compared with the negligible effect of other normal human serum (Fig. 2) . A neutralizing antibody monospecific for IL-5 markedly attenuated the eosinophil viability-sustaining activity in the serum from the three patients with EMS studied (Fig. 3) , as observed also for three patients with steroid-unresponsive IHES (16 (18) (19) (20) (21) (22) (23) (24) (25) . These findings suggest an increase in activity of indoleamine 2,3-dioxygenase in the presence of increased substrate load. This mechanism has been proposed in a report of a scleroderma-like illness developing in an individual ingesting 5-hydroxytryptophan and carbidopa in whom the peripheral eosinophil count was 1885 cells per mm3, and plasma levels of serotonin and L-kynurenine were also elevated (26) .
The elevated serum and urine levels of eosinophil major basic protein and eosinophil-derived neurotoxin in patients with EMS suggest ongoing eosinophil degranulation (6) as an alternative or concurrent pathobiologic process. Although eosinophils are not prominent histologically in affected organs, eosinophil-granule major basic protein has been found in several organs of a patient with EMS (6). Eosinophil granule proteins are known to be cytotoxic to a variety of mammalian tissues (27) , including peripheral nerve cells (28) . The ability of IL-5 alone to induce eosinophil degranulation in the absence of a ligand and to greatly enhance ligandstimulated eosinophil degranulation (29) suggests that this cytokine may contribute to the occurrence of tissue degranulation in EMS. The combined effects of tissue ischemia secondary to micropathic angiopathy and of eosinophilderived neurotoxins have been considered to be of pathobiologic significance (30) .
In summary, IL-5, the predominant eosinophilopoietic factor in the serum of patients with EMS, may contribute to the tissue injury by expanding the peripheral blood population of hypodense eosinophils that are primed for augmented biologic responses to activating stimuli. The finding that IHES and EMS both are characterized by greatly increased serum levels of IL-5 and phenotypically altered peripheral blood eosinophils but differ by the relatively diminished involvement of visceral organs in EMS suggests that local factors determine the tissue distribution of the eosinophils. The distribution of these primed, phenotypically altered eosinophils may be determined by the tissue source of the IL-5 or by a chemotactic/chemokinetic factor derived from the involved tissue that recruits cells already responding to IL-5, or by both.
